The global intravenous (IV) solutions market is expected to witness steady growth, supported by an aging population, the rising prevalence of chronic diseases, and increasing demand for parenteral nutrition. The COVID-19 pandemic also highlighted the importance of IV solutions in treating critically ill patients. However, the market continues to face challenges related to product safety, manufacturing costs, and regulatory compliance. Supply resilience has also come into focus after the 2024 U.S. IV fluid shortage. Technological advancements and strategic collaborations are expected to support innovation and competition across the industry.
Market Introduction
Intravenous fluids refer to sterile fluids that are directly infused in a patient's vein using needles and catheters. Such fluids can be made up of water, electrolytes, nutrients, or other substances and are used for purposes like hydration, drug administration, and intravenous nutrition. Their significance is especially high in hospitals and other medical facilities where patients cannot intake sufficient amounts of fluids or nutrients by oral means.
According to the initial market analysis quoted in the article, the global intravenous solutions market was worth US$9,907.8 Million in 2022. However, the recent analysis provided by the Coherent Market Insights (CMI) firm forecasts the market value at US$11.77 Billion in 2026 and predicts its increase to US$18.29 Billion by 2033, demonstrating the CAGR of 6.5% from 2026 to 2033.
3 Key Market Trends
- Increased need for ready-to-use IV formulations: Increasingly, there has been a need for sterile formulations that require fewer preparation steps and facilitate uniform delivery. Premixed norepinephrine bitartrate in 5% dextrose injection was launched in the U.S market by Baxter International after being approved by the U.S Food and Drug Administration in September 2021, which the CMI report describes as the first manufacturer-prepared ready-to-use formulation of its kind. Impact: ready-to-use products can reduce preparation steps and the risk of compounding errors, and they give manufacturers differentiated, approval-backed products, which supports the launches and regulatory approvals that CMI names as the main growth driver.
- Increased demand for parenteral nutrition: Parenteral nutrition is the administration of nutrition into the body via the veins for individuals who are not able to obtain adequate nutrition through digestion. This demand has been fuelled by complicated surgeries, critical care, chemotherapy and intestinal illnesses. Development of products in this category opens up new prospects for manufacturers who provide amino acid solutions, vitamins, minerals and nutritional mixtures. Impact: CMI cites parenteral nutrition launches as the second main growth driver and links them to North America's strong position, so the trend raises demand for higher-value nutritional and mixed solutions beyond basic fluids.
- Need for increased product safety and availability: IV formulations must have stringent sterility and quality standards since any contamination or formulation mistakes can put the patients' lives at risk. Recalls and disruptions of supply are key considerations within the industry. Therefore, manufacturers need reliable processes for producing and supplying the products to hospitals and other healthcare institutions. This became visible in September 2024, when Hurricane Helene shut Baxter's North Cove, North Carolina, plant, which supplied roughly 60% of U.S. IV fluids. Hospitals rationed supplies, the plant was fully operational again in February 2025, and the FDA declared the national shortage of 0.9% sodium chloride injection over in August 2025, although some other IV fluids remained in shortage. Impact: the event pushed buyers and manufacturers toward more diversified supply and added capacity, as seen in the 2025 joint venture between ICU Medical and Otsuka Pharmaceutical Factory.
Market Intelligence Context
According to the research carried out by CMI, the market size for intravenous solutions is estimated to grow from US$11.77 billion in 2026 to US$18.29 billion in 2033 at a CAGR of 6.5%. The study finds that some of the key drivers include new product launches, regulatory approvals, and development of parenteral nutrition products. However, recall of intravenous products has been cited as one of the restraining factors.
The intravenous solutions market consists of global and regional drug and infusion product manufacturers. Competition is determined by the quality of the product, regulatory compliance, manufacturing capabilities, distribution channels, and meeting the varying clinical needs.
Market Segmentation
The CMI report classifies the IV solutions market into five key categories:
- By solution: Saline, dextran, lactated Ringer’s, amino acids, vitamins and minerals, heparin and trace elements, and combined solutions.
- By bag type: Large bags larger than 250 ml and small bags smaller than 250 ml.
- By application: Basic IV solutions, nutritional IV solutions, blood IV solutions, drug IV solutions, and irrigation IV solutions.
- By end-user: Hospitals, clinics, ambulatory surgery centers, and home health care.
- By region: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
These categories encompass a variety of applications of the IV products in healthcare practices.
Detailed Sub-Segment Analysis
- The Lactated Ringer’s solution is an electrolyte solution that is used in the replacement of fluid to maintain the balance of electrolytes. This solution is mostly used in perioperative care, emergency medicine, and fluid loss cases. The demand for lactated Ringer’s solutions will be fueled by its application in surgeries, trauma treatment, and hospitals for the management of fluid and electrolyte levels. For instance, a study conducted by Intermountain Healthcare in June 2022 found that lactated Ringer’s solution reduces the chances of kidney injury and death by 2.2% as compared to the saline solution. However, fluid selection should continue to be patient-based.
- Nutritional IV solutions supply nutrients to patients who have problems obtaining sufficient nutrition through orally-ingested food or enteral nutrition. Nutritional IV products consist of amino acids, vitamins, minerals, and other compounds that are used in parenteral nutrition. The relevance of nutritional IV products includes critical care, certain cancer therapies, surgery, and gastroenterological problems that interfere with proper nutrient absorption.
The demand for these products depends on the special requirements of patients regarding nutrition and the development of new parenteral nutrition products. Hospitals are one of the important end users of these products due to the fact that these organizations deal with patients requiring special nutrition, while other settings may need to develop certain formulas for particular medical cases. Nutritional IV products should be properly formulated and sterile.
U.S. Country Analysis
The United States represents an important market for intravenous solutions based on the existing hospital network, demand for acute and critical care services, and use of injectable drugs and parenteral nutrition products. According to CMI, the market size for intravenous solutions in the United States is expected to be US$3.91 billion in 2026 and increase to US$ 6.45 billion by 2033, with a CAGR of 7.4%.
The driving factors include surgeries, treatment of chronic and acute conditions, as well as fluid and electrolyte management. In addition to hospitals, clinics, ambulatory surgery centers, and home-based care represent additional areas of potential market demand. The approval of the product as well as the development of ready-to-use formulas may foster the market adoption provided that clinical need and convenience of use is addressed. It is equally important to comply with the FDA regulations and manage the risks related to product recall and supply problems. Clinical comparison research between the frequently used intravenous fluids such as lactated Ringer’s and saline, is also part of clinical evaluation of fluids selection process.
Market Participants and Key Companies
-
Baxter International Inc.
Baxter International Inc. is an international organization that specializes in producing medical equipment, drugs, and biotechnology products. The firm was founded in 1931 and its headquarters are located in Deerfield, Illinois. Its North Cove plant supplied roughly 60% of U.S. IV fluids before Hurricane Helene in 2024 and returned to full operation in February 2025. In September 2021 Baxter launched premixed norepinephrine in 5% dextrose in the U.S. The IV portfolio by Baxter is applicable for hospital administration of fluids and medications.
SWOT Analysis
- Strengths:
- Presence in the hospitals and sterile injectable products market.
- Experience in ready-to-use sterile formulations.
- Weaknesses:
- Vulnerability to manufacturing and quality control problems.
- Production could be impacted by facility problems.
- Opportunities:
- Premixed IV drugs and solutions demand.
- Increasing need for critical care and parenteral nutrition.
- Threats:
- Regulatory issues that could impact product availability.
- Competition from other large sterile injectable manufacturers.
-
ICU Medical Inc.
San Clemente-based ICU Medical is a company focused on making infusion therapy, critical care, and oncology products. The company was founded in 1984 and operates internationally. ICU Medical made an announcement in September 2021 regarding the company’s decision to acquire Smiths Medical, which was completed in January 2022. In May 2025 it completed a joint venture with Otsuka Pharmaceutical Factory: Otsuka holds 60% of the IV solutions business (now Otsuka ICU Medical LLC), ICU Medical keeps 40% and sells and distributes the products, and the partners cite combined production of an estimated 1.4 billion units a year.
SWOT Analysis
- Strengths:
- Solid base in infusion therapy products.
- Diversification post Smiths Medical takeover.
- Weaknesses:
- Acquisition integration process may be challenging.
- Performance is partly reliant on hospitals' budget allocations.
- Opportunities:
- Growing need for integrated infusion and IV delivery systems.
- Further growth across hospitals and specialty care facilities.
- Threats:
- Intense rivalry in the field of infusion systems.
- Safety concerns regarding product reliability.
-
B. Braun Melsungen AG
B. Braun Melsungen AG is a German medical and pharmaceutical company established in 1839 and headquartered in Melsungen. It manufactures equipment and medications for healthcare institutions. In March 2022, B. Braun purchased Intermedt Medizin & Technik GmbH, which specializes in preparing dialysis concentrates. The range of healthcare solutions from B. Braun AG connects to infusion therapy and clinical fluids management.
SWOT Analysis
- Strengths:
- Extensive track record in medical products.
- Wide healthcare range from medical devices to pharmaceuticals.
- Weaknesses:
- Intricate product line needs significant regulation.
- Global operations make the supply chain more complex.
- Opportunities:
- Need for sterile fluids and hospital-infusion products.
- Increase in fluid management services.
- Threats:
- Competition from international medical-product companies.
- Production and regulatory issues could disrupt the supply process.
-
Grifols, S.A.